Dataset Information


Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.

ABSTRACT: The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.

SUBMITTER: Gharaibeh M 

PROVIDER: S-EPMC4402455 | BioStudies | 2015-01-01

SECONDARY ACCESSION(S): 10.1038/bjc.2015.65

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7222249 | BioStudies
1000-01-01 | S-EPMC5110585 | BioStudies
2019-01-01 | S-EPMC6500312 | BioStudies
2015-01-01 | S-EPMC4689963 | BioStudies
1000-01-01 | S-EPMC5470857 | BioStudies
2020-01-01 | S-EPMC7467417 | BioStudies
2013-01-01 | S-EPMC3884120 | BioStudies
2017-01-01 | S-EPMC5360414 | BioStudies
2013-01-01 | S-EPMC4269206 | BioStudies
2020-01-01 | S-EPMC7408795 | BioStudies